IN
Incyte
INCY · NASDAQ
$126.75 +0.23% (+$0.29)
1M +5.13%
Market Cap $25.9B
P/E Ratio 16.09x
Div. Yield -
ROE 29.70%
Bulios Fair Price
$149.37
17.8% upside
Current Price
$126.75
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INCY is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
75 /100
Cheap P/B 4.09x
P/S 4.46x
P/E 16.09x
Growth
85 /100
Growing Book val. growth 5.75%
FCF growth 14.94%
EPS growth 61.56%
Profitability
100 /100
Strong FCF margin 33.00%
Op. margin 31.57%
Gross margin 92.62%
Quality
94 /100
Excellent Asset turnover 0.74x
ROA 20.48%
ROIC 22.92%
Debt
100 /100
Low Net debt/EBITDA -1.93x
Int. coverage 847.54x
Debt/Equity 0.01x
Stability
68 /100
Stable Profitable years 5
EPS volatility 2,416.72%
Beta 0.77x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INCY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
William J. Meury
Employees
2,844
Headquarters
Wilmington
Upcoming events
27 OCT
Earnings
Upcoming earnings report